AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).
文献类型：期刊论文
| 作者 | Socinski, Mark A.; Spira, Alexander I.; Paz-Ares, Luis G.; Reck, Martin; Lu, Shun; Nishio, Makoto; Li, Jiang; Zhou, Yunfei; Rhee, Joon Whan; Duque, Sandra Chica |
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2021-05-20 |
| 卷号 | 39 |
| ISSN号 | 0732-183X |
| DOI | 10.1200/JCO.2021.39.15_suppl.TPS9128 |
| 资助项目 | BeiGene, Ltd. - BeiGene, Ltd |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000708120307040 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 资助机构 | BeiGene, Ltd. - BeiGene, Ltd |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126500]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Advent Hlth Hematol & Oncol, Orlando, FL USA 2.NYU, US Oncol Network, US Oncol Res, Virginia Canc Specialists, Fairfax, VA USA 3.Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain 4.German Ctr Lung Res, Lung Clin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany 5.Shanghai Chest Hosp, Shanghai, Peoples R China 6.Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan 7.BeiGene US Co Ltd, San Mateo, CA USA 8.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 9.Zhejiang Canc Hosp, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Socinski, Mark A.,Spira, Alexander I.,Paz-Ares, Luis G.,et al. AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
| APA | Socinski, Mark A..,Spira, Alexander I..,Paz-Ares, Luis G..,Reck, Martin.,Lu, Shun.,...&Yu, Xinmin.(2021).AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC)..JOURNAL OF CLINICAL ONCOLOGY,39. |
| MLA | Socinski, Mark A.,et al."AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。